Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis
- 5 May 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (9) , 1755-1760
Abstract
Background: Successful revascularization of coronary artery disease, especially ST-elevation myocardial infarction (STEMI), does not always mean optimal myocardial reperfusion in a portion of patients because of no-reflow phenomenon. We hypothesized that statins might attenuate the incidence of myocardial no-reflow when used before percutaneous coronary intervention (PCI). The purpose of this study was to summarize the evidence of pre-procedural statin therapy to reduce myocardial no-reflow after PCI. Methods: We searched the MEDLINE, Cochrane, and clinicaltrials.gov databases from inception to October 2012 for clinical trials that examined statin therapy before PCI. We required that studies initiated statins before PCI and reported myocardial no-reflow. A DerSimonian-Laird model was used to construct random-effects summary risk ratios. Results: In all, 7 studies with 3086 patients met our selection criteria. The use of pre-procedural statins significantly reduced post-procedural no-reflow by 4.2% in all PCI patients (risk ratio (RR) 0.56, 95% confidence interval (CI) 0.35 to 0.90, P=0.016), and attenuated by 5.0% in non-STEMI patients (RR 0.41, 95% CI 0.18 to 0.94, P=0.035). This benefit was mainly observed in the early or acute intensive statin therapy populations (RR 0.43, 95% CI 0.26 to 0.71, P=0.001). Conclusions: Acute intensive statin therapy before PCI significantly reduces the hazard of post-procedural no-reflow phenomenon. The routine use of statins before PCI should be considered.Keywords
This publication has 33 references indexed in Scilit:
- Coronary no reflowJournal of Molecular and Cellular Cardiology, 2012
- Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionAmerican Heart Journal, 2011
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Impact of Chronic Pre-Treatment of Statins on the Level of Systemic Inflammation and Myocardial Perfusion in Patients Undergoing Primary AngioplastyThe American Journal of Cardiology, 2011
- Effect of Previous Treatment With Statins on Outcome of Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary InterventionThe American Journal of Cardiology, 2009
- Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary interventionEuropean Heart Journal, 2008
- Meta-Analysis of the Role of Statin Therapy in Reducing Myocardial Infarction Following Elective Percutaneous Coronary InterventionThe American Journal of Cardiology, 2007
- Pretreatment with simvastatin reduces myocardial no‐reflow by opening mitochondrial KATP channelBritish Journal of Pharmacology, 2006
- Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarctionEuropean Heart Journal, 2006
- No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary interventionAmerican Heart Journal, 2003